Trade Cytori Therapeutics - PSTV CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 1.74 |
Open* | 1.8 |
1-Year Change* | 361.54% |
Day's Range* | 1.64 - 1.89 |
52 wk Range | 0.97-7.20 |
Average Volume (10 days) | 235.95K |
Average Volume (3 months) | 14.59M |
Market Cap | 8.28M |
P/E Ratio | -100.00K |
Shares Outstanding | 4.52M |
Revenue | 3.75M |
EPS | -6.18 |
Dividend (Yield %) | N/A |
Beta | 0.66 |
Next Earnings Date | Feb 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 29, 2023 | 1.65 | -0.15 | -8.33% | 1.80 | 1.89 | 1.64 |
Nov 28, 2023 | 1.74 | 0.04 | 2.35% | 1.70 | 1.76 | 1.70 |
Nov 27, 2023 | 1.67 | 0.08 | 5.03% | 1.59 | 1.78 | 1.59 |
Nov 24, 2023 | 1.61 | -0.09 | -5.29% | 1.70 | 1.76 | 1.60 |
Nov 22, 2023 | 1.79 | 0.05 | 2.87% | 1.74 | 1.86 | 1.74 |
Nov 21, 2023 | 1.79 | -0.03 | -1.65% | 1.82 | 1.82 | 1.69 |
Nov 20, 2023 | 1.85 | -0.23 | -11.06% | 2.08 | 2.46 | 1.64 |
Nov 17, 2023 | 2.59 | 0.24 | 10.21% | 2.35 | 2.72 | 2.13 |
Nov 16, 2023 | 2.15 | 0.28 | 14.97% | 1.87 | 2.20 | 1.85 |
Nov 15, 2023 | 1.86 | 0.24 | 14.81% | 1.62 | 1.88 | 1.62 |
Nov 14, 2023 | 1.66 | 0.26 | 18.57% | 1.40 | 1.71 | 1.40 |
Nov 13, 2023 | 1.43 | 0.03 | 2.14% | 1.40 | 1.45 | 1.37 |
Nov 10, 2023 | 1.37 | -0.07 | -4.86% | 1.44 | 1.48 | 1.35 |
Nov 9, 2023 | 1.47 | -0.10 | -6.37% | 1.57 | 1.59 | 1.44 |
Nov 8, 2023 | 1.56 | -0.12 | -7.14% | 1.68 | 1.68 | 1.53 |
Nov 7, 2023 | 1.63 | 0.11 | 7.24% | 1.52 | 1.66 | 1.52 |
Nov 6, 2023 | 1.58 | 0.12 | 8.22% | 1.46 | 1.59 | 1.42 |
Nov 3, 2023 | 1.56 | 0.07 | 4.70% | 1.49 | 1.64 | 1.36 |
Nov 2, 2023 | 1.34 | 0.11 | 8.94% | 1.23 | 1.51 | 1.21 |
Nov 1, 2023 | 1.25 | -0.05 | -3.85% | 1.30 | 1.33 | 1.19 |
Cytori Therapeutics Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, December 5, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Plus Therapeutics Inc at San Antonio Breast Cancer Symposium Plus Therapeutics Inc at San Antonio Breast Cancer SymposiumForecast -Previous - |
Wednesday, February 21, 2024 | ||
Time (UTC) 15:00 | Country US
| Event Q4 2023 Plus Therapeutics Inc Earnings Release Q4 2023 Plus Therapeutics Inc Earnings ReleaseForecast -Previous - |
Thursday, April 18, 2024 | ||
Time (UTC) 14:00 | Country US
| Event Q1 2024 Plus Therapeutics Inc Earnings Release Q1 2024 Plus Therapeutics Inc Earnings ReleaseForecast -Previous - |
Friday, April 19, 2024 | ||
Time (UTC) 14:00 | Country US
| Event Plus Therapeutics Inc Annual Shareholders Meeting Plus Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0.224 | 0 | 0.303 | 6.998 | 6.654 |
Revenue | 0.224 | 0 | 0.303 | 6.998 | 6.654 |
Cost of Revenue, Total | 2.373 | ||||
Gross Profit | 4.281 | ||||
Total Operating Expense | 19.936 | 12.492 | 9.887 | 10.655 | 19.352 |
Selling/General/Admin. Expenses, Total | 10.238 | 6.853 | 6.406 | 5.29 | 8.357 |
Research & Development | 9.698 | 5.323 | 2.7 | 5.365 | 8.622 |
Interest Expense (Income) - Net Operating | |||||
Unusual Expense (Income) | 0 | 0.316 | 0.781 | 0 | |
Operating Income | -19.712 | -12.492 | -9.584 | -3.657 | -12.698 |
Interest Income (Expense), Net Non-Operating | -0.563 | -0.907 | 1.343 | 1.607 | 0.354 |
Other, Net | 0 | -1.233 | -0.29 | ||
Net Income Before Taxes | -20.275 | -13.399 | -8.241 | -3.283 | -12.634 |
Net Income After Taxes | -20.275 | -13.399 | -8.241 | -3.283 | -12.634 |
Net Income Before Extra. Items | -20.275 | -13.399 | -8.241 | -3.283 | -12.634 |
Net Income | -20.275 | -13.399 | -8.241 | -10.887 | -12.634 |
Total Adjustments to Net Income | 0 | -0.554 | -2.487 | ||
Income Available to Common Excl. Extra. Items | -20.275 | -13.399 | -8.241 | -3.837 | -15.121 |
Income Available to Common Incl. Extra. Items | -20.275 | -13.399 | -8.241 | -11.441 | -15.121 |
Diluted Net Income | -20.275 | -13.399 | -8.241 | -11.441 | -15.121 |
Diluted Weighted Average Shares | 1.75035 | 0.80599 | 0.2952 | 0.09227 | 0.01159 |
Diluted EPS Excluding Extraordinary Items | -11.5834 | -16.6244 | -27.9163 | -41.5835 | -1304.59 |
Diluted Normalized EPS | -11.5834 | -16.2323 | -25.2707 | -41.5835 | -1304.59 |
Total Extraordinary Items | 0 | -7.604 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 1.854 | 0.506 | 0.151 | 0.073 | 0 |
Revenue | 1.854 | 0.506 | 0.151 | 0.073 | |
Total Operating Expense | 3.344 | 5.226 | 5.723 | 5.167 | 5.12 |
Selling/General/Admin. Expenses, Total | 1.924 | 2.243 | 3.585 | 2.222 | 2.289 |
Research & Development | 1.42 | 2.983 | 2.138 | 2.945 | 2.831 |
Operating Income | -1.49 | -4.72 | -5.572 | -5.094 | -5.12 |
Interest Income (Expense), Net Non-Operating | 0.008 | -0.083 | -0.086 | -0.125 | -0.162 |
Net Income Before Taxes | -1.482 | -4.805 | -5.658 | -5.219 | -5.282 |
Net Income After Taxes | -1.482 | -4.805 | -5.658 | -5.219 | -5.282 |
Net Income Before Extra. Items | -1.482 | -4.805 | -5.658 | -5.219 | -5.282 |
Net Income | -1.482 | -4.805 | -5.658 | -5.219 | -5.282 |
Income Available to Common Excl. Extra. Items | -1.482 | -4.805 | -5.658 | -5.219 | -5.282 |
Income Available to Common Incl. Extra. Items | -1.482 | -4.805 | -5.658 | -5.219 | -5.282 |
Diluted Net Income | -1.482 | -4.805 | -5.658 | -5.219 | -5.282 |
Diluted Weighted Average Shares | 2.50938 | 2.32013 | 2.24356 | 1.82954 | 1.48373 |
Diluted EPS Excluding Extraordinary Items | -0.59058 | -2.071 | -2.52188 | -2.85264 | -3.55995 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.59058 | -2.07014 | -2.52188 | -2.85264 | -3.55995 |
Unusual Expense (Income) | 0 | 0 | |||
Gain (Loss) on Sale of Assets | 0 | -0.002 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 21.817 | 19.724 | 9.175 | 19.825 | 9.648 |
Cash and Short Term Investments | 18.12 | 18.4 | 8.346 | 17.552 | 5.261 |
Cash & Equivalents | 18.12 | 18.4 | 8.346 | 17.552 | 5.261 |
Total Receivables, Net | 0 | 1.313 | 0.178 | ||
Accounts Receivable - Trade, Net | 0 | 1.169 | 0.178 | ||
Total Inventory | 0 | 0.107 | 0.107 | ||
Other Current Assets, Total | 0.007 | 0.059 | 0.04 | 4.102 | |
Total Assets | 23.867 | 21.981 | 12.105 | 23.229 | 23.991 |
Property/Plant/Equipment, Total - Net | 1.572 | 1.818 | 2.456 | 2.96 | 2.299 |
Goodwill, Net | 0.372 | 0.372 | 0.372 | 0.372 | 0.372 |
Intangibles, Net | 0.094 | 0.051 | 0.086 | ||
Other Long Term Assets, Total | 0.012 | 0.016 | 0.016 | 0.072 | 11.672 |
Total Current Liabilities | 11.852 | 5.87 | 8.539 | 14.486 | 17.559 |
Payable/Accrued | 0.245 | 2.777 | |||
Notes Payable/Short Term Debt | 1.608 | 1.608 | 6.335 | 0 | 14.202 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0.01 | 11.18 | |
Total Liabilities | 17.422 | 11.145 | 9.074 | 22.069 | 18.766 |
Total Long Term Debt | 3.786 | 5.005 | 0 | 0.008 | 0 |
Long Term Debt | 3.786 | 5.005 | |||
Other Liabilities, Total | 1.784 | 0.27 | 0.535 | 7.575 | 1.207 |
Total Equity | 6.445 | 10.836 | 3.031 | 1.16 | 5.225 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
Common Stock | 0.034 | 0.016 | 0.007 | 0.004 | 0 |
Additional Paid-In Capital | 473.596 | 457.73 | 436.535 | 426.426 | 418.39 |
Retained Earnings (Accumulated Deficit) | -467.185 | -446.91 | -433.511 | -425.27 | -414.383 |
Other Equity, Total | 0 | 1.218 | |||
Total Liabilities & Shareholders’ Equity | 23.867 | 21.981 | 12.105 | 23.229 | 23.991 |
Total Common Shares Outstanding | 2.2402 | 1.03405 | 0.44996 | 0.25872 | 0.01977 |
Property/Plant/Equipment, Total - Gross | 3.532 | 3.233 | 3.843 | 3.981 | 0 |
Accrued Expenses | 1.88 | 1.529 | 1.137 | 2.973 | 0 |
Other Current Liabilities, Total | 0 | 0.122 | 0.023 | 0.006 | 0.58 |
Prepaid Expenses | 3.697 | 1.317 | 0.77 | 0.813 | |
Accumulated Depreciation, Total | -1.96 | -1.415 | -1.387 | -1.021 | |
Accounts Payable | 8.364 | 2.611 | 0.789 | 0.327 | |
Capital Lease Obligations | 0 | 0.008 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 11.584 | 12.364 | 13.629 | 21.817 | 20.879 |
Cash and Short Term Investments | 11.006 | 10.895 | 12.723 | 18.12 | 20.266 |
Cash & Equivalents | 11.006 | 10.895 | 12.723 | 18.12 | 20.266 |
Other Current Assets, Total | 0.487 | 0.751 | 0.906 | 3.697 | 0.54 |
Total Assets | 13.278 | 14.197 | 15.638 | 23.867 | 23.104 |
Property/Plant/Equipment, Total - Net | 1.241 | 1.385 | 1.546 | 1.572 | 1.728 |
Goodwill, Net | 0.372 | 0.372 | 0.372 | 0.372 | 0.372 |
Intangibles, Net | 0.049 | 0.064 | 0.079 | 0.094 | 0.113 |
Other Long Term Assets, Total | 0.032 | 0.012 | 0.012 | 0.012 | 0.012 |
Total Current Liabilities | 10.538 | 11.399 | 12.796 | 11.852 | 7.42 |
Payable/Accrued | 6.073 | 6.58 | 6.495 | 10.134 | 5.705 |
Accrued Expenses | 0.117 | 0.11 | 0.107 | 0.11 | 0.107 |
Notes Payable/Short Term Debt | 4.348 | 4.709 | 5.057 | 1.608 | 1.608 |
Current Port. of LT Debt/Capital Leases | 0 | ||||
Total Liabilities | 10.656 | 11.535 | 12.962 | 17.422 | 11.7 |
Total Long Term Debt | 0 | 0 | 0 | 3.786 | 4.108 |
Capital Lease Obligations | |||||
Other Liabilities, Total | 0.118 | 0.136 | 0.166 | 1.784 | 0.172 |
Total Equity | 2.622 | 2.662 | 2.676 | 6.445 | 11.404 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Common Stock | 0.005 | 0.003 | 0.036 | 0.034 | 0.032 |
Additional Paid-In Capital | 479.308 | 476.131 | 474.63 | 473.596 | 472.899 |
Retained Earnings (Accumulated Deficit) | -476.691 | -473.472 | -471.99 | -467.185 | -461.527 |
Total Liabilities & Shareholders’ Equity | 13.278 | 14.197 | 15.638 | 23.867 | 23.104 |
Total Common Shares Outstanding | 4.52266 | 2.87962 | 2.40838 | 2.2402 | 2.17144 |
Long Term Debt | 0 | 0 | 0 | 3.786 | 4.108 |
Total Receivables, Net | 0.091 | 0.718 | 0.073 | ||
Other Current Liabilities, Total | 1.137 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -20.275 | -13.399 | -8.241 | -10.887 | -12.634 |
Cash From Operating Activities | -12.972 | -10.28 | -8.434 | -5.906 | -11.975 |
Cash From Operating Activities | 0.619 | 0.395 | 0.366 | 0.896 | 2.004 |
Non-Cash Items | 0.958 | 1.486 | -0.678 | 5.023 | -0.313 |
Cash Interest Paid | 0.327 | 0.388 | 0.567 | 1.188 | 1.331 |
Changes in Working Capital | 5.726 | 1.238 | 0.119 | -0.938 | -1.032 |
Cash From Investing Activities | -0.759 | -0.082 | -0.493 | 5.57 | -0.133 |
Capital Expenditures | -0.509 | -0.144 | -0.493 | -0.067 | -0.133 |
Other Investing Cash Flow Items, Total | -0.25 | 0.062 | 0 | 5.637 | 0 |
Cash From Financing Activities | 13.451 | 20.416 | -0.319 | 12.631 | 7.168 |
Financing Cash Flow Items | 0 | -1.598 | |||
Total Cash Dividends Paid | |||||
Issuance (Retirement) of Stock, Net | 15.059 | 20.692 | 5.105 | 16.454 | 8.766 |
Issuance (Retirement) of Debt, Net | -1.608 | -0.276 | -5.424 | -3.823 | 0 |
Foreign Exchange Effects | 0 | -0.004 | 0.016 | ||
Net Change in Cash | -0.28 | 10.054 | -9.246 | 12.291 | -4.924 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.805 | -20.275 | -14.617 | -9.398 | -4.116 |
Cash From Operating Activities | -5.793 | -12.972 | -10.738 | -6.516 | -3.876 |
Cash From Operating Activities | 0.158 | 0.619 | 0.46 | 0.302 | 0.147 |
Non-Cash Items | 0.208 | 0.958 | 0.749 | 0.528 | 0.284 |
Cash Interest Paid | 0.073 | 0.327 | 0.248 | 0.168 | 0.087 |
Changes in Working Capital | -1.354 | 5.726 | 2.67 | 2.052 | -0.191 |
Cash From Investing Activities | -0.097 | -0.759 | -0.748 | -0.715 | -0.577 |
Capital Expenditures | -0.097 | -0.509 | -0.498 | -0.465 | -0.327 |
Cash From Financing Activities | 0.493 | 13.451 | 13.352 | 6.921 | 7.292 |
Issuance (Retirement) of Stock, Net | 0.895 | 15.059 | 14.558 | 7.725 | 7.694 |
Issuance (Retirement) of Debt, Net | -0.402 | -1.608 | -1.206 | -0.804 | -0.402 |
Net Change in Cash | -5.397 | -0.28 | 1.866 | -0.31 | 2.839 |
Other Investing Cash Flow Items, Total | 0 | -0.25 | -0.25 | -0.25 | -0.25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cytori Therapeutics Company profile
About Plus Therapeutics Inc
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Plus Therapeutics Inc revenues decreased from $303K to $0K. Net loss increased 63% to $13.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 97% to $5.2M (expense), Change in fair value of liability instru decrease of 100% to $6K (income).
Equity composition
Common Stock $.001 Par, 02/11, 95M auth., 51,963,679 issd. Insiders own 14.62% IPO:N/A. 05/16, 1-for-15 reverse stock split.
Industry: | Biotechnology & Medical Research (NEC) |
4200 Marathon Blvd Ste 200
AUSTIN
TEXAS 78756-3433
US
Income Statement
- Annual
- Quarterly
News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com